NextCure (NASDAQ: NXTC) Chief Scientific Officer to step down Sept. 1, 2025

Rhea-AI Filing Summary

NextCure, Inc. announced that Chief Scientific Officer Solomon Langermann, Ph.D., resigned from his position effective September 1, 2025. His decision to step down is stated as not the result of any disagreement with the company’s operations, policies, or practices.

The board and company publicly thanked Dr. Langermann for his scientific leadership and many contributions during his tenure. The filing does not describe a successor or changes to the company’s scientific programs, focusing instead on the timing and amicable nature of his departure.

Insights

Biotech governance and leadership analyst

NextCure’s chief scientific officer is resigning in an amicable, non-dispute departure.

NextCure, Inc. reports that Chief Scientific Officer Solomon Langermann, Ph.D., will leave effective September 1, 2025. The company explicitly notes that his resignation is not due to any disagreement over operations, policies, or practices, framing this as an orderly leadership change.

For R&D-driven companies, the CSO role is central to scientific strategy and pipeline decisions. While this notice does not describe program or strategic changes, it confirms the board’s appreciation of his contributions and offers no indication of internal conflict. Subsequent company communications may clarify succession plans and the impact, if any, on ongoing scientific initiatives.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0001661059false00016610592025-08-212025-08-21

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2025

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation) 001-38905
(Commission File Number) 47-5231247
(IRS Employer Identification No.)

​ ​
9000 Virginia Manor Road, Suite 200 Beltsville, Maryland		20705
(Address of principal		(Zip Code)
executive offices)

Registrant's telephone number, including area code: (240) 399-4900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 21, 2025, Solomon Langermann, Ph.D., resigned from his position as Chief Scientific Officer of NextCure, Inc. (the “Company”), effective September 1, 2025. Dr. Langermann’s decision to resign was not the result of any disagreement with the Company or any matter relating to the operations, policies or practices of the Company.

​

The Company and its Board of Directors thank Dr. Langermann for his scientific leadership at the Company and are grateful for his many valuable contributions during his tenure.

​

​

​

​

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

November
Dated: August 25, 2025	NEXTCURE, INC. ​
	By:	/s/ Steven P. Cobourn
	Name:	Steven P. Cobourn
	Title:	Chief Financial Officer

​

​

​

​

​

FAQ

What did NextCure (NXTC) disclose in this Form 8-K?

NextCure (NXTC) disclosed that Chief Scientific Officer Solomon Langermann, Ph.D., has resigned effective September 1, 2025. The company emphasized that his departure is not due to any disagreement with its operations, policies, or practices, and expressed appreciation for his leadership.

When is NextCure’s Chief Scientific Officer resignation effective?

The resignation of NextCure’s Chief Scientific Officer, Solomon Langermann, Ph.D., is effective September 1, 2025. The company reported the decision date as August 21, 2025 and later filed the Form 8-K to formally notify investors of this leadership transition.

Did Solomon Langermann, Ph.D., resign from NextCure over a disagreement?

No, the filing states that Solomon Langermann, Ph.D., did not resign because of any disagreement with NextCure. It specifically notes no disagreement on company operations, policies, or practices, suggesting an amicable departure rather than a dispute-driven leadership change.

What role did Solomon Langermann, Ph.D., hold at NextCure (NXTC)?

Solomon Langermann, Ph.D., served as Chief Scientific Officer of NextCure, Inc. The filing highlights his scientific leadership and notes that the company and its board are grateful for his many valuable contributions to NextCure’s work during his tenure.

How did NextCure’s board describe Solomon Langermann’s contributions?

NextCure’s board and the company thanked Solomon Langermann, Ph.D., for his scientific leadership and expressed gratitude for his many valuable contributions. This language underscores a positive relationship at the end of his tenure, despite his decision to step down as Chief Scientific Officer.

Who signed the Form 8-K reporting the CSO resignation for NextCure?

The Form 8-K reporting the Chief Scientific Officer’s resignation was signed on behalf of NextCure by Steven P. Cobourn, the company’s Chief Financial Officer. His signature indicates that the report was duly authorized under the Securities Exchange Act requirements.